A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL ON PHYTOSOMAL CURCUMIN: EFFECTS ON EPIGENETICS AND OXIDATIVE STRESS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER

Background and Aim: This clinical trial aimed to discover the effects of phytosomal curcumin on MLH1 and MSH2 promoter methylation, and oxidative stress among non-alcoholic fatty liver patients.Methods: Fifty patients with non-alcoholic fatty liver aged 20-65 years were assigned to two groups in this randomized, double-blind, controlled clinical trial. Patients in the intervention group consumed 250 mg/day curcumin, while those in the control group consumed starch as placebo. Fasting blood samples, anthropometric measurements, and 24-h dietary recalls were collected at the baseline and at the end of the study. Results: Curcumin significantly decreased promoter methylation in proximal and distal MLH1 promoter region and MSH2 promotor region (P < 0.05) compared with the baseline values, while plasma concentration of 8-hydroxy-2 -deoxyguanosine (8-OHdG) didn t change significantly (P > 0.05). The result of between group comparison indicated non-significant changes in liver enzymes (Alanine transaminase (ALT) Aspartate transaminase (AST)) and anthropometric variables. Conclusion: The consumption of phytosomal curcumin decreased promoter methylation of MLH1 and MSH2 among non-alcoholic fatty liver patients, indicating that curcumin is a promising agent for the enhancement of proof reading enzymes expression among these patients.

کلیدواژه ها:

Oxidative stress ، Curcumin ، Promoter methylation ، Non-alcoholic fatty liver